CureVac (NASDAQ:CVAC) Stock Price Up 3.9% – Should You Buy?

CureVac (NASDAQ:CVAC)’s stock price was up 3.9% during trading on Tuesday . The company traded as high as $2.94 and last traded at $2.94. Approximately 59,314 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 859,065 shares. The stock had previously closed at $2.83.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a “market outperform” rating and set a $16.00 target price on shares of CureVac in a research report on Monday, September 16th.

CureVac Trading Down 3.1 %

The stock has a fifty day moving average price of $3.01 and a 200 day moving average price of $3.24. The stock has a market cap of $626.86 million, a PE ratio of -2.09, a PEG ratio of 2.07 and a beta of 2.62. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.28 and a current ratio of 2.29.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). CureVac had a negative net margin of 422.66% and a negative return on equity of 57.18%. The firm had revenue of $15.55 million for the quarter, compared to the consensus estimate of $10.07 million. Equities analysts expect that CureVac will post 0.05 EPS for the current year.

Institutional Trading of CureVac

Institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC purchased a new stake in shares of CureVac in the third quarter worth approximately $30,000. International Assets Investment Management LLC purchased a new position in CureVac during the 3rd quarter valued at $35,000. Bank of New York Mellon Corp bought a new position in CureVac in the 2nd quarter valued at $54,000. Ballentine Partners LLC increased its stake in CureVac by 58.6% in the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock worth $67,000 after purchasing an additional 8,406 shares during the period. Finally, Signaturefd LLC lifted its position in shares of CureVac by 232.0% during the second quarter. Signaturefd LLC now owns 22,043 shares of the company’s stock worth $75,000 after purchasing an additional 15,403 shares during the last quarter. Institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.